HRTX vs PACB

For growth investors, Heron Therapeutics, Inc.

(HRTX) is the stronger pick with 7. 4% revenue growth year-over-year, versus 3. 9% for Pacific Biosciences of California, Inc. (PACB). Analysts rate Heron Therapeutics, Inc. (HRTX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Heron Therapeutics, Inc.

(HRTX) delivered a total return of -92. 5%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: PACB returned -84. 0% versus HRTX's -93. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Heron Therapeutics, Inc.

(HRTX) is the lower-risk stock at 1. 81β versus Pacific Biosciences of California, Inc. 's 2. 41β — meaning PACB is approximately 33% more volatile than HRTX relative to the S&P 500. On balance sheet safety, Heron Therapeutics, Inc. (HRTX) carries a lower debt/equity ratio of 10% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Heron Therapeutics, Inc.

(HRTX) is pulling ahead at 7. 4% versus 3. 9% for Pacific Biosciences of California, Inc. (PACB). On earnings-per-share growth, the picture is similar: Heron Therapeutics, Inc. grew EPS -34. 7% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, HRTX leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Heron Therapeutics, Inc.

(HRTX) is the more profitable company, earning -13. 0% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps -13. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HRTX leads at -1. 6% versus -348. 5% for PACB. At the gross margin level — before operating expenses — HRTX leads at 73. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Heron Therapeutics, Inc.

(HRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HRTX: -93. 0%, PACB: -84. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.